Life Sciences - COTA Healthcare

Advance with clarity

When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.

Our Approach

COTA leverages our proprietary abstraction technology and oncology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.

We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.

Our Value

Read Customer Case Study:

Read Customer Case Study:

Read Customer Case Study:

Our Difference

Data Source

Abstraction

Flexibility

Curation Depth

Our Products

*Complexity based on ability to define, curate, and deliver; can include additional biomarkers, labs, imaging, pathology, and more.

Getting Focused

Where does our data come from?

COTA captures clinical data from EHR from multiple provider sources across the United States, including both academic and community cancer programs. We also use non-EHR sources such as publicly available and proprietary databases, to generate a rich and precise dataset for use by life sciences companies.

What types of data does COTA collect?

COTA collects all clinically-relevant data points to create a rich, in-depth longitudinal cancer patient journey from our healthcare providers’ EHR. Data elements captured may vary per cancer type, but generally, our data contains (but is not limited to) detailed demographic, pathologic, genomic, treatment, and outcomes data.

How can life science companies use COTA data?

Life sciences companies have used our data to support HEOR, commercial assessments, and clinical development, including supplementing clinical trial data with RWD in the form of external comparator controls. We are open to discussing any other opportunities, as well as your data needs and how COTA can generate value for your organization.

What types of companies do we work with?

We work with life science companies interested in using oncology RWD to accelerate drug development and bring clarity to cancer. We work with the top global pharmaceutical companies, though our partners range from multinational pharma to emerging biotechs.

How does COTA work with emerging biopharma?

Our collaborative and flexible approach enables us to succeed with emerging biopharma partners. We work alongside EBPs to provide analytical, medical, and strategic support to validate use of COTA data towards EBP goals.

Is COTA compliant with regulatory requirements?

COTA is ISO-certified, HIPAA-compliant, and aligns with 21 CFR Part 11 regulations.

Latest Resources

So you want to train an oncology LLM: Start by getting close to the data

To create targeted LLMs that are suitable for diving into health-related areas like oncology, we must choose our data carefully and get as close to the original source as possible to avoid “playing telephone” with inaccurate information that could affect drug development processes or cancer outcomes.

COTA Wins Google Cloud Customer of the Year Award for using AI to Improve Cancer Care

A panel of senior Google Cloud executives selected COTA from a pool of entries to win *2* Google Cloud Customer Awards. These awards showcase companies from around the world who are using Google Cloud technologies to improve their operations, and their social and governance efforts.

COTA Joins Aetion CARE Initiative

In this episode of Real World Talk, host Sandy Leonard sits down with Ulka Campbell, Head of Scientific Strategy at Aetion, and CK Wang, Chief Medical Officer at COTA. They dive into the Aetion CARE program, a cross-industry initiative aimed at understanding real-world data’s role in evaluating oncology therapeutics.

Interested in learning more about how we can transform cancer care together?